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Background: When ingested in a blood meal, ivermectin has been shown to reduce the survivorship of Anopheles
gambiae in the laboratory and field. Furthermore, ivermectin mass drug administrations in Senegal have been
shown to reduce the proportion of Plasmodium falciparum-sporozoite-containing An. gambiae. This study addresses
whether ivermectin inhibits sporogony of P. falciparum in An. gambiae.
Methods: Anophele gambiae s.s. G3 strain were fed two concentrations of ivermectin (LC25 and LC5) along with
P. falciparum NF54 in human blood meals at staggered intervals. Mosquitoes ingested ivermectin concurrent with
parasites (DPI 0), or at three (DPI 3), six (DPI 6), and nine (DPI 9) days post parasite ingestion, or three days prior
(DPI −3) to parasite ingestion. Mosquitoes were dissected at seven, twelve or fourteen days post parasite ingestion
and either oocyst or sporozoite prevalence was recorded. To determine if P. falciparum sporozoite-containing An.
gambiae were more susceptible to ivermectin than uninfected controls, survivorship was recorded for mosquitoes
which ingested P. falciparum or control blood meal on DPI 0 and then a second blood meal containing ivermectin
(LC25) on DPI 14.
Results: Ivermectin (LC25) co-ingested (DPI 0) with parasites reduced the proportion of An. gambiae that developed
oocysts (χ2 = 15.4842, P = 0.0002) and sporozoites (χ2 = 19.9643, P < 0.0001). Ivermectin (LC25) ingested DPI 6
(χ2 = 8.5103, P = 0.0044) and 9 (χ2 = 14.7998, P < 0.0001) reduced the proportion of An. gambiae that developed
sporozoites but not when ingested DPI 3 (χ2 = 0.0113, P = 1). Ivermectin (LC5) co-ingested (DPI 0) with parasites
did not reduce the proportion of An. gambiae that developed oocysts (χ2 = 4.2518, P = 0.0577) or sporozoites
(χ2 = 2.3636, P = 0.1540), however, when ingested DPI −3 the proportion of An. gambiae that developed
sporozoites was reduced (χ2 = 8.4806, P = 0.0047). Plasmodium falciparum infection significantly reduced the
survivorship of An. gambiae that ingested ivermectin (LC25) on DPI 14 compared to control mosquitoes that
ingested a primary blood meal without parasites (χ2 = 4.97, P = 0.0257).
Conclusions: Ivermectin at sub-lethal concentrations inhibits the sporogony of P. falciparum in An. gambiae. These
findings support the utility of ivermectin for P. falciparum transmission control.
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Novel Anopheles vector control methods are needed
for current malaria elimination and eradication efforts
[1]. Ivermectin mass drug administration (MDA) to
humans has been suggested as a possible vector con-
trol method to reduce Plasmodium transmission [2-8].
Ivermectin MDA to humans meets several of the cri-
teria outlined by the Malaria Eradication Research* Correspondence: kevin.c.kobylinski.ctr@us.army.mil
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novel vector control interventions, including: the abil-
ity to target exophagic and exophilic vectors, integra-
tion with current vector control efforts [5,6], novel
mode of action [9,10] from the currently used insecti-
cides [11], avoids known mosquito behavioural and
physiological resistance mechanisms, and can affect the
vector population age structure [7].
The vectorial capacity equation provides a framework
that defines the factors that regulate Plasmodium trans-
mission by Anopheles vectors [12]. The current vectorral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ticides and long lasting insecticide treated nets primarily
affect the daily probability of mosquito survivorship
and/or reduce vector-host contact [13,14]. However,
there are several other variables in the vectorial capacity
equation that vector control methods could impact
which would reduce Plasmodium transmission.
The most influential variable of vectorial capacity is
the daily probability of mosquito survivorship [12,15]. In
vitro laboratory studies have demonstrated that ivermec-
tin can reduce the daily probability of survivorship of
numerous Anopheles Plasmodium-vectors, including
Anopheles gambiae s.s. at physiologically relevant con-
centrations found in humans after ingestion of ivermec-
tin [4,16,17]. The second most influential variable of the
vectorial capacity equation is the daily probability of a
mosquito feeding on a human, which is a factor of the
mosquito host preference index and the feeding fre-
quency. Anopheles gambiae s.s. blood-feeds almost ex-
clusively on humans with a median host preference
index of 0.939 [18]. The feeding frequency of An. gam-
biae s.s. was significantly delayed when ivermectin was
ingested in a blood meal at mosquito sub-lethal concen-
trations [4,19]. The vector density relation to the host is
another variable of vectorial capacity that may be
affected by ivermectin MDA. Ivermectin not only
reduces the survivorship of An. gambiae s.s., but it also
causes a knockdown effect and a recovery delay post
blood feeding [19] which likely further reduces mosquito
populations due to desiccation, starvation, and preda-
tion. Ivermectin has also been shown to reduce An. gam-
biae fecundity [16]. This laboratory evidence and
modelling data [7] suggests that vector density in rela-
tion to the host may be temporarily reduced after iver-
mectin MDA to humans, but this remains to be
demonstrated in a field setting.
Ivermectin MDAs to humans are performed annually in
many parts of sub-Saharan Africa for Onchocerca volvulus
transmission suppression by the African Program for On-
chocerciasis Control (APOC) and Wuchereria bancrofti
transmission suppression by the Global Programme to
Eliminate Lymphatic Filariasis [20]. In south-eastern Sene-
gal, indoor-resting blood-fed An. gambiae s.l. were col-
lected before and after routine APOC ivermectin MDAs
from three pairs of treated and control villages and this
work clearly demonstrated that An. gambiae s.s. survivor-
ship was significantly reduced for approximately one week
following ivermectin MDA [5]. Further analysis of field-
collected mosquitoes revealed that ivermectin MDA also
reduced the proportion of Plasmodium falciparum
sporozoite-containing (i.e. infectious) An. gambiae s.s. for
at least two weeks post-MDA [6].
There are several possible explanations for this reduc-
tion in the proportion of P. falciparum-infectious An.gambiae s.s, which are not exclusive of each other. Mod-
elling has predicted that the An. gambiae population age
structure following ivermectin MDA temporarily shifts
to younger age classes, therefore, fewer P. falciparum-
infectious mosquitoes are present for several weeks [7].
Field work is currently being performed in Senegal to
gather empirical evidence as to whether this population
age structure shift occurs. It may also be that P. falcip-
arum-infectious mosquitoes are more susceptible than
non-infected mosquitoes to ivermectin and thus are pre-
ferentially removed from the population of mosquitoes.
Finally, ivermectin may be sporontocidal and thus lower
the proportion or prevalence of Anopheles ingesting an
infective Plasmodium blood meal that successfully be-
come infectious or lengthen the extrinsic incubation
period of Plasmodium in the Anopheles vector. These lat-
ter three possibilities were explored below in laboratory
experiments with P. falciparum and An. gambiae s.s.
Methods
Parasites
Gametocyte cultures of P. falciparum (NF54) line were
cultured in vitro following the modified Trager and Jen-
sen method [21,22] in human erythrocytes group O+
(Key Biologics LLC, Memphis, TN) and RPMI 1640
medium (Life Technologies, Grand Island, NY) supple-
mented with 25 mM HEPES, 25 mM NaHCO3, 50 mg/L
hypoxanthine (Sigma-Aldrich, St. Louis, MO) and 10%
(v/v) type A+ human serum (Key Biologics LLC, Mem-
phis, TN). Media was changed daily and parasites were
blood fed to mosquitoes 15 days post subculture. For
mosquito blood meals cultures were transferred from
flasks to 50 ml conical tubes and centrifuged at 1600
RPMs for ten minutes at 37°C and culture media super-
natant was removed. Red blood cells (RBCs) and human
serum were mixed in a 1:1 ratio and fed to mosquitoes
via glass membrane feeders sealed with parafilm at 37°C.
Mosquitoes
Anopheles gambiae s.s. (G3 strain) were obtained from
the National Institutes of Health, raised at 26 -27°C, 80%
relative humidity, and a 12:12 light:dark cycle. Larvae
were raised on a diet of ground TetraminW fish food.
Adults were provided 10% sucrose solution ad libitum.
Adult mosquitoes were between four and seven days
post emergence when they were fed a P. falciparum-
infectious blood meal.
LC50 calculations
The powdered ivermectin formulation was obtained
from Sigma-Aldrich (St. Louis, MO). Ivermectin was
diluted in dimethyl sulfoxide (DMSO) to 10 mg/ml and
aliquots were frozen at −20°C. Frozen aliquots of iver-
mectin were thawed and serially diluted in phosphate
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consisting of packed RBCs and human serum mixed 1:1
heated to 37°C prior to mixing. Ten μl of varied concen-
trations of ivermectin in PBS were added to 990 μl of
blood meal to reach the final concentrations offered to
mosquitoes. Multiple concentrations of ivermectin were
fed to adult An. gambiae s.s. between four and seven
days post emergence to determine the lethal concentra-
tion that killed 50%, 35%, 25%, and 5% of the mosquitoes
(LC50, LC35, LC25, and LC5). After blood feeding, 50 fully
engorged mosquitoes were gently transferred by aspir-
ation to 0.5 L cardboard cartons and held in a different
incubator at 26°C, 80% relative humidity, and a 12:12
light:dark cycle. Engorged mosquitoes were held for
seven days with access to 10% sucrose solution and sur-
vivorship was monitored every 24 hours and dead mos-
quitoes were removed from the containers daily. Six
replicates were performed.
Effect of ivermectin on Plasmodium falciparum sporogony
Anopheles gambiae s.s. were fed cultured gametocytae-
mic RBCs with various concentrations of ivermectin,
LC25 and LC5, and at various time points in relation to
the infectious blood meals. Ivermectin-(LC25)-contain-
ing blood meals were administered concomitantly with
parasites (DPI 0), or three (DPI 3), six (DPI 6), and
nine (DPI 9) days after (post) the infectious (DPI)
blood meal. Ivermectin-(LC5)-containing blood meals
were administered concomitantly with parasites (DPI
0), or three (DPI −3) days before parasites. Control
mosquitoes were fed in a separate container with the
same blood meal schedule, only ivermectin was
replaced with DMSO at equivalent concentrations in
PBS. After blood feeding, fully engorged mosquitoes
were gently transferred by aspiration to new 3.8 L
cardboard cartons and held in a different incubator at
26°C, 80% relative humidity, and a 12:12 light:dark
cycle. Mosquitoes were held for fourteen days after the
infectious blood feed with 10% sucrose solution ad libi-
tum. Mosquitoes fed ivermectin (LC25 and LC5) con-
comitantly with infectious gametocytes (DPI 0) were
dissected on day post infection (DDPI) 7 and oocysts
were enumerated. Midguts were dissected with forceps
into saline on a microscope slide and stained for 15
minutes in methylene blue (0.1%) (Fisher Scientific, Fair
Lawn, NJ), pressed between a cover slip and viewed at
200X magnification with a MT5000 Series biological
microscope (Meiji Techno, Santa Clara, CA). A delay
in blood meal digestion caused by ivermectin [4]
ingested on DPIs 3 and 6 obscured the ability to view
oocysts on the midgut, therefore, prevalence and inten-
sity were not determined at those time points. On
DDPI 12 and 14, salivary glands were dissected with
forceps into saline on a microscope slide, pressedbetween a cover slip, and viewed at 200X magnification
with a MT5000 Series biological microscope. Preva-
lence of sporozoites in salivary glands were recorded
for each mosquito. Four replicates of ivermectin (LC5
or LC25) concentration and DPI (−3, 0, 3, 6, or 9) com-
binations were performed and approximately twenty
mosquitoes were dissected for each control and treat-
ment group on each DDPI. Two additional replicates
of ivermectin (LC25) DPI 0 were performed in order to
obtain enough visible midguts with oocyst infections
for statistical analyses.
Effect of Plasmodium falciparum infection on mosquito
survivorship post ivermectin ingestion
Anopheles gambiae s.s. were fed either gametocytaemic
or non-gametocytaemic control blood meals and held in
the insectary for fourteen days in 3.8 L cartons. On DPI
14, ten mosquitoes were dissected as described above to
confirm at least 90% P. falciparum sporozoite presence
in salivary glands. If the mosquitoes met the infection
criteria status, then both infected and control cartons
were fed a secondary ivermectin (LC25)-containing blood
meal. Approximately 50 mosquitoes were transferred by
aspiration to 0.5 L cartons and held as described above.
Mosquito survivorship was monitored every 24 hours
and dead mosquitoes were removed from the containers
daily until all mosquitoes were dead. Five replicates were
performed.
Statistical analysis
A non-linear mixed model with probit analysis was used
to calculate LC50, LC35, LC25, and LC5 values as
described previously [4]. The proportion of mosquitoes
with oocysts or sporozoites was compared by Fisher’s
Exact test. In order to determine if ivermectin length-
ened the extrinsic incubation period the rates of change
in the proportion of sporozoite positive mosquitoes be-
tween DDPI 12 and DDPI 14 were analyzed by logistic
regression (SAS Proc GLIMMIX) [23] with effects for
treatment (ivermectin, control), period (DDPI 12, DDPI
14), and treatment by period with replicate as a random
effect. The treatment by period interaction tests
whether the change in the proportion of sporozoite
positive mosquitoes between DDPI 12 and DDPI 14 dif-
fers between ivermectin and control treatments. These
above statistical analyses were performed with Statistical
Analysis Software (SAS Institute Inc., Cary, NC). Oocyst
intensity was compared by the Mann–Whitney U test.
To determine if P. falciparum infection altered mos-
quito survivorship post-ivermectin ingestion survival
analysis data were analysed by the Mantel-Cox method.
Mann–Whitney U tests and Mantel-Cox tests were per-
formed with PRISM 5 (GraphPad Software, Inc., San
Diego, CA).
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LC50 calculations
The lethal concentrations of ivermectin fed to An. gam-
biae s.s. were calculated as: LC50 = 15.9 ng/ml 95% C.I.
[14.6, 17.3], LC35 = 12.7 ng/ml [11.3, 13.9], LC25 = 10.7
ng/ml [9.3, 12.0], LC5 = 6.1 ng/ml [4.8, 7.4] (n = 3355).Figure 2 Proportion of Anopheles gambiae that contained
sporozoites when ivermectin (LC25) was ingested DPIs 3, 6, 9.
When ivermectin (LC25) was fed at DPI 3 post parasites it did not
reduce the proportion of An. gambiae that contained sporozoites
at DDPI 12 (χ2 = 4.3718, P = 0.0556, n = 112) or at DDPI 14
(χ2 = 0.0113, P = 1, n = 145). However, when ivermectin (LC25) was
fed at DPIs 6 and 9 post parasites it reduced the proportion of
An. gambiae that contained sporozoites on DPI 6 at DDPI 12
(χ2 = 12.4919, P = 0.0006, n = 95) and at DDPI 14 (χ2 = 8.5103,
P = 0.0044, n = 135) and on DPI 9 at DDPI 12 (χ2 = 16.2056,
P < 0.0001, n = 132) and at DDPI 14 (χ2 = 14.7998, P < 0.0001,
n = 161). * significantly different P < 0.05, DPI = days post infection,
DDPI = dissected at day post infection.Effect of ivermectin on Plasmodium falciparum sporogony
When ivermectin (LC25) was co-ingested with P. falcip-
arum (ie. DPI 0) it reduced the prevalence or proportion
of An. gambiae that developed oocysts at DDPI 7 (χ2 =
15.4842, P = 0.0002, n = 89) and sporozoites at DDPI 12
(χ2 = 13.4741, P = 0.0003, n = 97) and at DDPI 14 (χ2 =
19.9643, P < 0.0001, n = 136) (Figure 1). The oocyst in-
tensity per successfully infected mosquito fed ivermectin
(LC25) (mean = 21.0 ± 2.93 s.e.) at DPI 0 was not
reduced relative to controls (mean = 21.5 ± 2.94 s.e.) (P =
0.8139, n = 136). When ivermectin (LC25) was ingested on
DPI 3, it did not reduce the proportion of An. gambiae
that contained sporozoites at DDPI 12 (χ2 = 4.3718, P =
0.0556, n = 112) or at DDPI 14 (χ2 = 0.0113, P = 1, n =
145) (Figure 2). However, ivermectin (LC25) ingested on
DPI 6 and DPI 9 reduced the proportion of An. gambiae
that contained sporozoites at DDPI 12 and DDPI 14 [DPI
6 at DDPI 12 (χ2 = 12.4919, P = 0.0006, n = 95) and DPI 6
at DDPI 14 (χ2 = 8.5103, P = 0.0044, n = 135); DPI 9 at
DDPI 12 (χ2 = 16.2056, P < 0.0001, n = 132) and DPI 9 at
DDPI 14 (χ2 = 14.7998, P < 0.0001, n = 161)] (Figure 2).Figure 1 Proportion of Anopheles gambiae that were infected
with Plasmodium falciparum when ivermectin (LC25) was
co-ingested with parasites (DPI 0). When ivermectin (LC25) was
co-ingested with P. falciparum at DPI 0 it reduced the prevalence or
proportion of An. gambiae that developed oocysts at DDPI 7
(χ2 = 15.4842, P = 0.0002, n = 89) and sporozoites at DDPI 12
(χ2 = 13.4741, P = 0.0003, n = 97) and at DDPI 14 (χ2 = 19.9643,
P < 0.0001, n = 136). * significantly different P < 0.05, DPI = days
post infection, DDPI = dissected at day post infection.When ivermectin (LC5) was co-ingested with P. falcip-
arum (DPI 0), it did not reduce the prevalence or propor-
tion of An. gambiae that developed oocysts at DDPI 7 (χ2 =
4.2518, P = 0.0577, n = 115) or sporozoites at DDPI 12
(χ2 = 0.5937, P = 0.5101, n = 149) or at DDPI 14 (χ2 =
2.3636, P = 0.1540, n = 156) (Figure 3). The oocyst intensity
per successfully infected mosquito fed ivermectin (LC5) on
DPI 0 (mean = 15.4 ± 2.53 s.e.) was not reduced compared
to controls (mean = 13.1 ± 2.34 s.e.) (P = 0.9278, n = 84).
However, when ivermectin (LC5) was ingested three days
before a P. falciparum blood meal (DPI −3) it reduced the
proportion of An. gambiae that contained sporozoites at
DDPI 12 (χ2 = 4.6333, P = 0.0406, n = 95) and at DDPI 14
(χ2 = 8.4806, P = 0.0047, n = 155) (Figure 4).
Ivermectin (LC25) did not delay the extrinsic incuba-
tion period of P. falciparum when ingested on DPI 0
(F-value = 0.01, P = 0.9308, n = 233), DPI 3 (F-value =
1.89, P = 0.2116, n = 257), DPI 6 (F-value = 0.27, P =
0.6182, n = 230), or DPI 9 (F-value = 0.08, P = 0.7796,
n = 295) nor did ivermectin (LC5) delay sporogony when
ingested at DPI 0 (F-value = 0.59, P = 0.4622, n = 304)
or DPI −3 (F-value = 0.01, P = 0.9238, n = 250).
Effect of Plasmodium falciparum infection on mosquito
survivorship post ivermectin ingestion
Plasmodium falciparum infection significantly reduced
the survivorship of An. gambiae that ingested ivermectin
Figure 3 Proportion of Anopheles gambiae that were infected
with Plasmodium falciparum when ivermectin (LC5) was
co-ingested with parasites (DPI 0). When ivermectin (LC5) was
co-ingested with P. falciparum on DPI 0 it did not reduce the
proportion of An. gambiae that developed oocysts at DDPI 7
(χ2 = 4.2518, P = 0.0577, n = 115) or sporozoites at DDPI 12
(χ2 = 0.5937, P = 0.5101, n = 149) or at DDPI 14 (χ2 = 2.3636,
P = 0.1540, n = 156).
Figure 5 Survivorship of Anopheles gambiae that ingested
ivermectin (LC25) at DPI 14. Plasmodium falciparum infection
significantly reduced the survivorship of An. gambiae that ingested
ivermectin on DPI 14 compared to control mosquitoes that received
a primary blood meal without parasites (χ2 = 4.97, P = 0.0257, n = 450).
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received a primary blood meal without P. falciparum (χ2 =
4.97, P = 0.0257, n = 450) (Figure 5). Preliminary data did
not indicate that P. falciparum reduced the survivorship
of An. gambiae that co-ingested ivermectin (LC35) on DPI
0 compared to control mosquitoes that received only a
blood meal (χ2 = 0.1054, P = 0.7454, n = 61), therefore,
further replicates were not performed. Preliminary data
indicated that P. falciparum infection compared to aFigure 4 Proportion of Anopheles gambiae that contained
sporozoites when ivermectin (LC5) was ingested DPI −3. When
ivermectin (LC5) was ingested three days before parasites (DPI −3) it
reduced the proportion of An. gambiae that contained sporozoites
at DDPI 12 (χ2 = 4.6333, P = 0.0406, n = 95) and at DDPI 14
(χ2 = 8.4806, P = 0.0047, n = 155).control blood meal on DPI 0 did not reduce An. gambiae
survivorship (χ2 = 0.3518, P = 0.5531, n = 59).Discussion
This study demonstrates that, in several different combi-
nations, ivermectin is sporontocidal and reduces the
prevalence or proportion of An. gambiae ingesting an in-
fective P. falciparum blood meal that become sporozoite
positive. Plasmodium falciparum-infectious An. gambiae
may be more susceptible to ivermectin compared to
non-infected mosquitoes. Ivermectin does not appear to
lengthen the extrinsic incubation period of P. falciparum
in An. gambiae.
Ivermectin (LC25) ingested concomitantly with para-
sites (DPI 0) had the most dramatic effect on P. falcip-
arum sporogony of any ivermectin concentration or DPI
combination (Figures 1–4). While the proportion of
mosquitoes that developed oocysts were reduced by iver-
mectin treatment, the number of oocysts per infected
mosquito was not reduced, which implies that ivermec-
tin exerts an ‘all-or-nothing’ effect on oocyst establish-
ment and development. There was a significant
reduction in parasite development when ivermectin
(LC25) was ingested at DPI 6 and DPI 9 but not at DPI 3
(Figure 2). This suggests that ivermectin can affect late-
stage but not early-stage oocyst development. Finally,
ivermectin (LC5) ingested on DPI 0 had no effect on
oocyst or sporozoite prevalence (Figure 3), however
when ivermectin (LC5) was ingested prior to parasites
(DPI −3) there was a significant reduction in sporozo-
ite prevalence (Figure 4). These results suggest that
ivermectin has a modulating effect on the mosquito
host environment that is unfavourable for sporogonic
development.
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mode of action of ivermectin on P. falciparum spor-
ogony, the data presented may offer some insight. Iver-
mectin is a lipophilic molecule that embeds itself in
membranes and interacts with transmembrane portions
of ion channels [24]. In invertebrates, ivermectin inter-
acts with glutamate-gated chloride ion channels in neur-
onal and neuromuscular tissues, which leads to flaccid
paralysis [9,10,25]. There may also be some interaction
of ivermectin with γ-aminobutyric acid-gated chloride
channels [26-28]. Neither of these chloride ion channels
are present in P. falciparum and ivermectin does not
have relevant activity against blood-stage P. falciparum
at concentrations found in humans post oral treatment.
Growth of blood-stage P. falciparum (K1 isolate) was
inhibited by ivermectin but the mean IC50 and IC90
values were 8.0 and 35.0 μg/ml [29] which are several
hundred to thousand times higher than concentrations
used in the current study (6.1 and 10.7 ng/ml) and nor-
mal levels found in human venous plasma after ingesting
ivermectin (150 μg/kg) [30]. Indeed, oral ivermectin
(200 μg/kg) treatment of P. falciparum-infected humans
had no effect on blood-stage parasites [31]. Similarly, no
relevant effects of ivermectin were demonstrated against
the Apicomplexa coccidian Eimeria muris or dozens of
species of bacteria and fungi [32]. Nevertheless, it may
be possible that unknown ivermectin targets specific to
sporogonic P. falciparum stages exist which may explain
the activity against late-stage but not early-stage oocysts
(Figure 2). The broad activity of ivermectin is evident from
recent in vitro evidence that demonstrates that ivermectin
can effect viral replication of human immunodeficiency
virus and several arthropod-transmitted Flaviviruses by
targeting virus NS3 helicase activity [33] or inhibiting
nuclear import [34].
The observed ‘all-or-nothing’ effect of ivermectin on
oocyst development in this report is more congruent
with a sporontocidal mechanism whereby ivermectin
acts on the mosquito rather than the parasite. Ivermec-
tin may alter some aspect of the mosquito midgut physi-
ology that impacts parasite development or the drug
may stimulate enhanced anti-Plasmodium innate im-
munity. Regarding the latter possibility, no melanized
oocysts from dissected midguts were observed from any
control or ivermectin-treated mosquitoes with any iver-
mectin concentration or DPI combination. The data
showing that ivermectin (LC5) only inhibits sporogony
when ingested DPI −3, but not at DPI 0, suggests that
this treatment may alter some aspect of the midgut
physiology that prevents parasite establishment, such as
mosquito peritrophic matrix formation or blood meal di-
gestion prior to parasite ingestion. Previous work has
shown ivermectin to delay the formation and reduce the
thickness of the peritrophic matrix in Aedes aegypti [35].Delays in blood meal digestion by An. gambiae that had
ingested an ivermectin-containing blood meal have been
reported previously [4] and were observed in these
experiments as well. There is a complex interaction of
the P. falciparum ookinete with the peritrophic matrix
[36,37] and the midgut epithelium [38], which may be
affected by ivermectin.
Previous investigators have found accelerated develop-
ment kinetics of wild strains of P. falciparum in wild
Anopheles in that most ookinetes were formed in the
blood meal before twenty-four hours [39], while with the
in vitro NF54 strain in colonized Anopheles the ooki-
netes were formed in the blood meal after twenty-four
hours [40-42]. The ivermectin studies presented here
should be replicated with wild P. falciparum isolates and
various An. gambiae strains and other Anopheles species
to ensure that the effects of ivermectin observed with
NF54 represent what occurs in the field. The effects of
ivermectin on other Plasmodium species in various
Anopheles species should be investigated as well.
Ivermectin did not appear to lengthen the extrinsic in-
cubation period (n), for any ivermectin concentration or
DPI combination. More frequent dissections and sporo-
zoite observation on DDPIs 10, 11, 13 and increased
replication would provide more data for the general lin-
ear mixed models which may be better than the inputs
used for this study. Extending dissections beyond DDPI
14 may not provide relevant information as the propor-
tion of infected control mosquitoes at DDPI 7 matched
the proportion of infectious control mosquitoes at DDPI
14 (χ2 = 0.2803, P = 0.6717, n = 135) and the proportion
of infected ivermectin-treated mosquitoes at DDPI 7
matched the proportion of infectious ivermectin-treated
mosquitoes at DDPI 14 (χ2 = 0.0, P = 1, n = 90) (Figure 1).
Alternative methods such as enumerating ruptured
oocysts at time points beyond DDPI 7 may be necessary
to determine if the extrinsic incubation is altered.
A significant, although modest, reduction in P. falcip-
arum-infectious An. gambiae survivorship compared to
uninfected counterparts was demonstrated (χ2 = 4.97,
P = 0.0257) (Figure 5). As the effect of P. falciparum
on Anopheles survivorship is debatable [43], further
experiments conducted with wild P. falciparum isolates
combined with enumeration of mosquito mortality
prior to ivermectin ingestion are necessary. A reduced
susceptibility of P. falciparum-infectious An. gambiae
to ivermectin combined with the fact that Plasmodium
sporozoite salivary gland infection alters mosquito be-
haviour would enhance the efficacy of ivermectin
MDA for Plasmodium transmission control. Plasmo-
dium-infectious vectors in the laboratory [44,45] and
the field [46,47] have increased mosquito host probing
and blood feed more frequently compared to unin-
fected mosquitoes. In Tanzania, wild P. falciparum-
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multiple people per night and feed to repletion com-
pared to uninfected counterparts [47]. Multiple
ivermectin-containing blood meals were found to com-
pound An. gambiae s.s. mortality at a greater rate than
a single ivermectin-containing blood meal [4]. As
roughly 80% of people in a village are treated with
ivermectin during routine MDAs, it follows that the
more frequent host feeding of P. falciparum-infectious
An. gambiae s.s. means that they are more likely to
imbibe a blood meal that contains ivermectin or mul-
tiple blood meals that contain ivermectin. These find-
ings may further explain some of the reduction in the
proportion of P. falciparum-infectious An. gambiae s.s.
post-ivermectin MDA [6], especially if P. falciparum-
infectious An. gambiae are more likely to die than
their uninfected counterparts.
Currently, it is not known how much ivermectin is
imbibed by a mosquito during blood feeding on an orally
treated human. Human pharmacokinetic data for oral
ivermectin treatment is based on venous blood samples
[30], however ivermectin is found in fat and dermal tis-
sue at two to three times greater concentrations than
venous plasma [48]. As mosquitoes blood feed from sub-
dermal capillaries, the amount of ivermectin imbibed
may differ from the amount present in venous plasma.
This makes it difficult to predict how long laboratory-
demonstrated mosquito sub-lethal sporontocidal effect
of ivermectin may impact P. falciparum transmission dy-
namics in the field following ivermectin MDA. Concur-
rent studies are attempting to quantify the concentration
of ivermectin imbibed by a mosquito compared to ven-
ous and capillary blood concentrations.
This study clearly demonstrates that ivermectin can
impact P. falciparum sporogony in An. gambiae which is
a critical factor to reduce Plasmodium transmission via
ivermectin MDA. Since ivermectin MDA has only been
demonstrated to reduce vector transmission, it may be
necessary to combine ivermectin MDA with anti-
malarial drug treatment to clear parasites from the
human population. One disadvantage of mass screening
and treatment (MSAT) with anti-malarial drugs is that
parasites may be transmitted between the screening and
treatment interval [49]. Ivermectin MDA may address
this MSAT shortcoming if ivermectin is delivered at the
point of sample collection to limit Plasmodium trans-
mission between sample processing and anti-malarial
drug treatment, however, the safety and efficacy of the
co-administration of ivermectin and anti-malarial drugs
remains to be validated. Plasmodium falciparum gam-
etocyte circulation time has been shown to be reduced
post artemisinin-based combination therapy (ACT) [50],
however, field evidence demonstrates that P. falciparum
transmission still occurs post-ACT treatment [51-54].Primaquine is effective against late-stage gametocytes
[55,56] and has been co-administered with ACT in an
effort to reduce Plasmodium transmission. However,
primaquine causes haemolysis in humans with glucose-
6-phosphate dehydrogenase deficiency [57,58] which
could reduce human compliance with the treatment
regimen. As ivermectin has sporontocidal, mosquito le-
thal, and mosquito sub-lethal effects that prevent Plas-
modium transmission, and does not cause haemolysis, it
may be an ideal agent to combine with ACT.
Conclusions
Ivermectin is sporontocidal to P. falciparum at concen-
trations sub-lethal to An. gambiae and that are present
in humans after oral treatment. Mosquito ingestion of
ivermectin inhibited sporogony in An. gambiae when
ingested before, with, or after parasite ingestion. Plasmo-
dium falciparum-infectious An. gambiae may be slightly
more susceptible to ivermectin than uninfected counter-
parts. As these studies were conducted with cultured P.
falciparum (NF54) and colonized An. gambiae s.s. (G3
strain) it will be necessary to validate results with wild P.
falciparum isolates and wild-caught An. gambiae or with
other Plasmodium and Anopheles species combinations.
These results further substantiate the utility of ivermec-
tin MDA to reduce P. falciparum transmission.
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